Femara
Letrozole, marketed primarily as Femara, is an orally active non-steroidal aromatase inhibitor (AI) developed by Novartis and approved by the FDA in 1997 for the treatment of hormone-receptor-positive breast cancer in postmenopausal women. It is a triazole-class competitive, reversible inhibitor that binds the heme iron of the aromatase enzyme (CYP19A1) and prevents the conversion of androgens into estrogens. Among clinically used aromatase inhibitors it is the most potent, producing > 99% whole-body aromatase suppression and plasma estradiol reductions approaching the assay limit of detection.
For off-label estrogen control, start at a very low dose - 0.25mg EOD or even 2x per week. Letrozole is the most potent AI available and crashing estradiol happens fast. Confirm a pre-cycle sensitive estradiol baseline and recheck at 10-14 days. Symptoms of over-suppression (joint pain, flat libido, depressive mood, dry skin, lipid damage) should drive a dose reduction or discontinuation immediately. For the FDA-approved breast cancer indication, 2.5mg daily is the standard dose.
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
Aromatase (CYP19A1) converts androgens - testosterone and androstenedione - into estrogens - estradiol and estrone. Letrozole is a triazole that competitively occupies the aromatase active site and coordinates to the heme iron, blocking substrate access. The binding is reversible, so enzyme activity returns as drug clears; this differs from the irreversible binding of exemestane.
Its high potency means very low doses produce near-complete suppression - clinical dosing of 2.5mg daily reduces plasma estradiol by more than 99% in postmenopausal women, and even 0.5mg produces near-maximal suppression in most individuals. For men on aromatizable cycles, this means the typical off-label dose is a small fraction of the cancer-treatment dose. Reversible binding also means estrogen rebounds quickly between doses if intervals are too long, so steady scheduling matters more than with exemestane.
Because Letrozole has no intrinsic androgenic activity (it is a synthetic triazole, not an androgen analog), it tends to produce a stronger lipid shift (HDL drop, LDL rise) than exemestane at equivalent estrogen suppression. Long-term use is also associated with measurable bone mineral density loss, a direct consequence of profound estrogen deprivation.
First 3-7 days: near-maximal aromatase suppression achieved. Estrogen-related water weight and blood pressure begin to drop. Joint pain may emerge within this window if the dose is too aggressive.
Weeks 2-4: estrogen stabilizes at the dose-dependent set point. Gynecomastia symptoms resolve in most users if dose is appropriate. This is the window to draw a sensitive E2 and fine-tune the dose - symptom-only dosing is not sufficient given Letrozole's potency.
Beyond 4 weeks on a stable dose: estrogen remains steady. Monitor lipids and bone markers on long runs. Post-cycle recovery of aromatase function is relatively quick (3-6 days to full return) because binding is reversible.
Each reference below was re-fetched from its PubMed record, and the quoted sentence was confirmed to appear in that abstract and to support the claim it sits under. Follow any of them to read the source.
Evidence boundary from the checked abstract: Efficacy end points continued to show trends favoring letrozole.
Efficacy end points continued to show trends favoring letrozole.
Evidence scope. This entry supports only the exact statement quoted from the live abstract; it does not independently verify OnePin's displayed dose, route, frequency, formulation, population, or broader mechanism.
Claims we could not support
No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.
Dose/route: 0.25mg; Oral; EOD or 2x weekly (off-label); daily (FDA-approved indication). No checked live PubMed abstract verified this exact displayed dose, route, and frequency for the same molecule/formulation and relevant population.
Primary safety claim: No primary safety text present in source JSON. No checked live PubMed abstract directly verified this source-JSON safety claim at the displayed formulation, route, and regimen.
Approximately 2 days
Oral
Aromatase suppression persists 24-48+ hours per dose - supports daily or every-other-day dosing. Steady state reached in roughly 2-6 weeks
Hepatic (CYP3A4 and CYP2A6). Renal excretion of metabolites as inactive glucuronide conjugate.
Storage. Store at controlled room temperature (20-25°C / 68-77°F). Protect from moisture and light. Keep in original container. Shelf life typically 3 years from manufacture date for tablets. Research-grade oral suspensions should be refrigerated after opening and used within 30-60 days. Keep out of reach of children.
Prescription medication (Rx) in the United States. FDA-approved brand: Femara (Novartis). Generic letrozole is widely available and significantly less expensive than branded Femara. Not a controlled substance. Off-label use in men for estrogen control or gynecomastia rescue is common but legally requires a valid prescription. Research liquid forms marketed for research purposes are not FDA-regulated for human use. Internationally classified as a prescription drug in most jurisdictions.
Put it to work
Open Letrozole (Femara) straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open Letrozole (Femara) in the app →Go deeper
The complete Letrozole (Femara) walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗Track it in OnePin. Log vials, draws, and protocols in the app.
Type a name, brand, or tool. Esc closes.